Global Cardiac Biomarkers Testing Market- Market Overview:

The Global Cardiac Biomarkers Testing market is expected to grow from USD 4 billion in 2022 to USD 7.4 billion by 2030, at a CAGR of 8% during the Projection period 2023-2030. The growth of this market is mainly driven owing to the rising incidences of cardiac attacks.

A blood test called an enzyme marker test measures particular biological markers, or biomarkers, in your blood. The presence of elevated or high levels of cardiac enzymes may indicate a heart attack or other heart condition. The term "cardiac biomarker" also refers to heart enzymes. Cardiac biomarkers assist medical professionals in determining whether a heart attack (myocardial infarction), angina, heart failure, or another issue is to blame for a patient's symptoms. Increases in cardiac enzymes might indicate myocardial ischemia or acute coronary syndrome (ACS). These conditions are treated in various ways. Making sure you receive the right care depends on a precise diagnosis. Healthcare professionals measure cardiovascular marker levels to Screen for heart disease and other issues. Determine the aetiology of cardiac disorders that result in symptoms including shortness of breath, angina, and chest pain, among others.

A blood sample must be taken for a cardiac enzyme marker test. It only takes a few minutes to draw blood. A hospital's emergency room or other medical facility draws blood in an emergency. The test may be performed at a blood testing lab or at your healthcare practitioner's office in less urgent circumstances. Cardiac biomarkers come in a variety of forms. They are all either proteins or enzymes. Elevated heart enzyme levels may indicate cardiovascular disease or other heart issues. The only organ that produces troponin is the heart, hence the main test used by medical professionals to identify heart damage from a heart attack or ACS is a biomarker test for this enzyme. After a heart attack, troponin levels might increase for up to 12 hours.

Sample Request: - Global Cardiac Biomarkers Testing Market

Market Dynamics:

Drivers:                          

• Adoption of crucial tactics for product launches

The market for cardiac biomarkers testing is expanding due to factors like rising healthcare costs, partnerships and collaborations between large players, and increased R&D. For instance, HeartFlow declared on July 15, 2021, that it would combine with Longview Acquisition Corp. II to become a publicly traded business. Through this merger, HeartFlow will be able to broaden its user base and advance its objective to revolutionize the continuum of treatment for people with heart disease. The leading companies in the sector are motivated by various strategies and concentrate on developing new test types and ongoing technology breakthroughs and product modifications. For instance, Abbott introduced the RX Implantable Cardiac Monitor (ICM) in May 2019, which monitors heartbeat to track heart rhythm.

Restraints:                                             

• Lack of qualified and experienced personnel

A team of highly certified, skilled, and experienced healthcare experts is needed to carry out an efficient cardiac catheterization operation because it is a challenging treatment that demands high precision and accuracy. It is anticipated that throughout the projection period, the market expansion will be somewhat constrained by a dearth of skilled specialists to perform coronary angiograms, particularly in emerging nations due to the absence of comprehensive training programs. According to a study by NCBI, approximately one million cardiac catheterization procedures will be performed annually on July 26. Despite significant advancements in cardiac catheterization equipment, improved operator skills, and adoption of cutting-edge procedures, patients’ and procedure-related issues still occur.

Opportunities:

• Increasing prevalence of cardiovascular diseases

Heart failure, myocardial infarction, acute coronary syndrome, and other cardiovascular disorders can all be detected and diagnosed early due to cardiac biomarkers. The World Health Organization (WHO) estimates that 32.4 million myocardial infarctions or strokes occur each year around the world. In addition, over 2.5 million hospitalizations globally are related to acute coronary syndrome (ACS), a frequent consequence of coronary heart disease. Thus, it is projected that the increased prevalence of cardiovascular disorders will spur demand for early detection and hasten the implementation of cardiac biomarker tests.

Challenges:

• Technical issues with sample storage and collecting

Cardiovascular biomarkers are utilized in epidemiology research to investigate various illness stages in people. This technique necessitates careful management and storage of priceless biological samples to get the most information out of a small number of samples. A strict quality check is required for these samples to provide the proper storage conditions and prevent data loss. The quality of the samples and how they are collected, handled, and stored will determine how successfully cardiac biomarker studies employing archived specimens are conducted. The total market for cardiac biomarkers, particularly laboratory-based testing, is projected to experience growth challenges due to technical problems with sample collection and storage.

Segmentation Analysis:

The global Cardiac Biomarkers Testing market has been segmented based on biomarker type, application, end-user, and region.

By Biomarker Type

The biomarker type segment includes troponin, Creatine Kinase-Mb, B-Type Natriuretic Peptide, and Others. The troponin segment led the Cardiac Biomarkers Testing market with a market share of around 29% in 2022. Compared to other tests, the diagnostic efficiency, specificity, and accurate prediction detection of cardiac events drive the segment’s growth. The global increase in myocardial infarction and stroke rates also helps the segment's growth. Due to its application in detecting stress and cardiac injury, the BNP and NT-proBNP segment is anticipated to grow significantly. For instance, LumiraDx Limited announced in June 2022 that its CE Mark for the D-Dimer and NT-proBNP tests would diversify its range. By the end of 2022, it is anticipated that the latter will be commercially available, which should make clinical decision-making easier.

By Application

The application segment includes acute coronary syndrome, congestive heart failure, myocardial infarction, and others. The acute coronary syndrome segment led the Cardiac Biomarkers Testing market with a market share of around 33% in 2022. The market is growing due to the sharp increase in disease burden in low- and middle-income nations relative to high-income countries. Rapid urbanization and a rise in sedentary jobs contribute to the disease's prevalence. The most common diagnostic tests used to identify the condition are cardiac troponin T and I biomarker testing.

By End-User

The end user segment is pathology labs, hospitals, and others. The pathology labs segment led the largest share of the Cardiac Biomarkers Testing market with a market share of around 39% in 2022. Most of the diagnosis of diseases using biomarkers is made in pathology, which increases the demand for cardiac biomarker testing in pathology labs. The demand for cancer biomarkers in pathology labs is increasing owing to their high sensitivity, specificity, scalability, and cost-effectiveness. Additionally, these labs make it possible to test any kind of sample, which are essential for clinical decision-making.

Global Cardiac Biomarkers Testing Market- Sales Analysis.

The sale of cardiac biomarkers testing market expanded at a CAGR of 7.9% from 2016 to 2022.

With the increasing prevalence of heart attacks and companies are spending money on R&D to create improved solutions for the Cardiac Biomarkers Testing industry. Due to the high prevalence of acute coronary syndrome, technological advancements in cardiac biomarkers testing, increasing demand for point-of-care (POC) cardiac testing kits, and high specificity in the detection of cardiac diseases, particularly myocardial infarction, cardiac biomarkers are experiencing growth. The need is also being fueled by the increased use of cardiac biomarkers in SARS-CoV-2 patients to reduce the risk of heart disorders. For instance, according to NCBI in 2021, increased levels of cardiac injury biomarkers were found in difficult COVID-19 patient cases, and these biomarkers were directly linked to poor illness prognoses. As a result, the use of cardiac biomarkers made it possible to manage patients with advanced illnesses.

A variety of combination tests that identify the presence of biomarkers are also included in cardiac test kits, making it easier to diagnose heart problems. These kits are in higher demand since they enable speedy diagnosis and prompt results, which cut down on the amount of time needed for diagnosis and speed up the healing process. Additionally, they aid in identifying risk factors before bad cardiac events happen and diagnose chest pain.

The prevalence of cardiovascular illnesses is predicted to rise, accelerating segment growth. According to the WHO, 17.9 million deaths globally from cardiovascular illnesses will occur annually by 2021, accounting for 32% of all fatalities. In the United States, cardiovascular illnesses constitute the main cause of mortality and morbidity. Since they help to understand the pathophysiology of cardiovascular disorders better, businesses are currently concentrating on identifying cardiac biomarkers. Roche Diagnostics' Elecsys Troponin T-Gen 5 STAT, a cardiac biomarker, provides data in 9 minutes and aids in prompt decision-making.

Thus, owing to the aforementioned factors, the global cardiac biomarker testing Market is expected to grow at a CAGR of 8% during the Projection period from 2023 to 2030.

Global Cardiac Biomarkers Testing Market- By Regional Analysis:

The regions analyzed for the Cardiac Biomarkers Testing market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. The North American region dominated the Cardiac Biomarkers Testing market and held a 39% share of the market revenue in 2022.

• The North American region witnessed a major share during the Projection period. This can be ascribed to the advanced healthcare system and the widespread use of cardiac biomarkers as a diagnostic and prognostic tool for diseases. The need for testing products is being driven by the growing elderly population's need for biomarker testing to diagnose diseases such as acute myocardial infarction. Another element boosting the expansion of this market is the presence of important firms like Quidel Corporation and Danaher Corporation in the region.
• Asia Pacific is anticipated to experience significant growth during the Projection period. Due to rising affordability for sophisticated cardiac testing, country modernization, and rising disposable income, the market in the region is growing. Government funding for target disease, other research, and healthcare costs have increased due to the rising incidence of cardiovascular diseases (CVDs) in this region. Compared to other developing nations, India has a greater prevalence of CVDs. Due to the high prevalence of disease in the region, there will likely be a rise in the need for cardiac biomarker diagnostics to aid in the early detection, assessment, and treatment of CVDs.

Global Cardiac Biomarkers Testing Market- Country Analysis:

• Germany

Germany's Cardiac Biomarkers Testing market size was valued at USD 0.31 billion in 2022 and is expected to reach USD 0.49 billion by 2030, at a CAGR of 6% from 2023 to 2030. The region's market is growing due to the steady increase in people suffering from conditions including peripheral artery disease and coronary artery disease, among others. According to data published by the European Union, cardiovascular diseases were the leading cause of death in Germany on March 21, 2022. Additionally, technical developments enable portable characteristics in testing equipment, supporting the expansion of the market's revenue.

• China

China’s Cardiac Biomarkers Testing’ market size was valued at USD 0.59 billion in 2022 and is expected to reach USD 1.05 billion by 2030, at a CAGR of 7.5% from 2023 to 2030. Due to the high prevalence of heart disease in some areas and the substantial patient population needing treatment in nations like China, the market in the region is growing. According to a report released by BioSpectrum on June 23, 2022, the number of heart attacks among people under 50 has dramatically grown in China over the past ten years. All age groups, including those under 50, have shown a rise in the age-specific incidence rate of heart attacks per 100,000 persons.

• India

India's Cardiac Biomarkers Testing market size was valued at USD 0.36 billion in 2022 and is expected to reach USD 0.61 billion by 2030, at a CAGR of 7% from 2023 to 2030. Over the Projection period, it is expected that the rising prevalence of cardiovascular diseases, improved healthcare facilities, the presence of major market players, and higher investment in research and development activities in the region will significantly impact the market for cardiac biomarker testing.

Key Industry Players Analysis:

To increase their market position in the global Cardiac Biomarkers Testing business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, partnerships, joint ventures, etc.

• Beckman Coulter, Inc
• Hoffmann-La Roche Ltd
• Abbott, bioMérieux SA
• Thermo Fischer Scientific Inc
• Bio-Rad Laboratories Inc
• Eurolyser Diagnostica GmbH
• Diagnostic Automation / Cortez Diagnostics, Inc
• Randox Laboratories Ltd
• Tosoh Corporation
• DIALAB GmbH
• CardioGenics Holdings Inc
• Lepu Medical Technology (Beijing) Co. Ltd.
• Biosynex
• Siemens Healthcare GmbH

Latest Development:

• In April 2021, Roche revealed a series of five new planned uses for two important cardiac biomarkers in April 2021 using the Elecsys technology, which has the NT-proBNP and high sensitive cardiac troponin T. (cTnT-hs). This is anticipated to enhance risk diagnosis and detection while enabling the business to increase income from its current goods.
• In November 2021, Royal Philips announced that it had reached an agreement to purchase Cardiologs, a French-based medical technology business that specialises in integrating AI and cloud technology to transform cardiac diagnostics. With cutting-edge software, ECG analysis, and reporting services, Cardiologs will further bolster Philips' cardiac monitoring and diagnostics offerings.

Report Metrics

Report Attribute	Details
Study Period	2022-2030
Base year	2022
CAGR (%)	8%
Market Size	4 billion in 2022
Projection period	2023-2030
Projection unit	Value (USD)
Segments covered	By Biomarker Type, By Application, By End-User, and By Region.
Report Scope	Revenue Projection, competitive landscape, company ranking, growth factors, and trends
Companies covered	Beckman Coulter, Inc, F. Hoffmann-La Roche Ltd, Abbott, bioMérieux SA, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex, and Siemens Healthcare GmbH.
By Biomarker Type	Troponin Creatine Kinase-Mb B-Type Natriuretic Peptide Others
By Application	Acute Coronary Syndrome Congestive Heart Failure Myocardial Infarction Others
By End-User	Pathology Labs Hospitals Others
Regional scope	North America Europe Asia-Pacific South America Middle East and Africa

Scope of the Report

Global Cardiac Biomarkers Testing Market By Biomarker Type:

• Troponin
• Creatine Kinase-Mb
• B-Type Natriuretic Peptide
• Others

Global Cardiac Biomarkers Testing Market By Application:

• Acute Coronary Syndrome
• Congestive Heart Failure
• Myocardial Infarction
• Others

Global Cardiac Biomarkers Testing Market By End-User:

• Pathology Labs
• Hospitals
• Others

Global Cardiac Biomarkers Testing Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Korea
  • Southeast Asia
• South America
  • Brazil
  • Peru
• Middle East and Africa
  • UAE
  • South Africa
  • Saudi Arabia

Political Factors- Several variables affect the profitability of the worldwide cardiac biomarkers testing market. Politics-related factors that could affect the industry include changes to tax laws, consumer protection, employment laws, and insurance obligations. For instance, a change in tax laws may need a strategy modification that either capitalizes on increasing government healthcare spending or accounts for decreased government subsidies. A significant shift in the workforce and overtime requirements may also result from changes in employment law, such as the 2016 legislation that affected employee overtime requirements.

Economical Factors- Examples of economic problems impacting healthcare companies' financial performance include unemployment, inflation, and interest rates. These shifting situations may impact the general public's purchasing power and expenditure policies. For instance, if a business produces cardiac biomarkers for healthcare, a high unemployment rate will result in fewer people being able to make purchases. Additionally, if fewer people can work, they will not be eligible for employment benefits, such as healthcare.

Social Factor- The cardiac biomarkers sector should be able to recognize shifts in the values, attitudes, and demography of your different consumer groups. To avoid going against accepted beliefs or conventions, a manufacturer, for instance, should be aware of the society it serves. These kinds of elements must be considered in the company's marketing plan as well. The effectiveness of marketing will increase, and it will positively affect performance if you use content that demonstrates alignment with a particular sociocultural set of beliefs/values.

Technological Factors- Cardiac biomarkers are expanding, and one factor driving to this expansion is increased R&D spending by healthcare companies. Spending on R&D and the release of new medications have both increased during the past 20 years. For instance, Investments in healthcare innovation are boosting contributions to the American economy and strengthening the nation's reputation as a leader in medical innovation. The current IQVIA report, which reflects trust in scientific innovation to address unmet health needs, states that investment in future medical advances grew in 2018. In 2018, venture capital firms made over $23 billion in investments, and the 15 top pharmaceutical corporations spent over $100 billion on R&D for the first time, an increase of 32% over the previous five years. A few technological characteristics are the speed of technological advancement, automation, R&D initiatives, and technology incentives. Today, technology is all around us, and the development of new technologies is likely to affect the industry.

Environmental Factors- For firms that assemble cardiac biomarkers, environmental sustainability measures have financial and environmental advantages. Environmentally friendly building designs are now being sought after by many firms, and waste disposal practices are also being scrutinized. Corporate social responsibility (CSR), which ought to be a significant component of any business plan, is demonstrated by leadership in green environmental practices. Implementing the closed-loop, the circular economy approach is starting to become the standard in several nations. Industries with enabling institutional frameworks facilitate material recycling and reuse.

Legal Factors- Laws pertaining to consumer protection, antitrust, employment, and health and safety regulations are only a few of them. These factors could affect a business' operations, costs, and product demand. Failure to abide by the new regulations and legal processes governing cardiac biomarkers could result in the immediate demise of a business and a market. The overall plan should consider the legal repercussions of ongoing cases, HIPAA compliance, future acquisitions, and more. Additionally, there is employment law, which is a catch-all word for a number of laws defending workers' rights, including fair pay, equality, equity, inclusion, and justice, as well as health and safety. While some nations lack efficient enforcement of employment laws, others have harsh penalties for violating any of the specified rights of employees. Therefore, breaking these regulations could result in severe consequences.

1. Introduction
   • 1. Objectives of the Study
   • 2. Market Definition
   • 3. Research Scope
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
   • 1. Porter’s Five Forces Analysis
   • 2. Value Chain Analysis
   • 3. Top Investment Pockets
     • 3.1. Market Attractiveness Analysis By Biomarker Type
     • 3.2. Market Attractiveness Analysis By Application
     • 3.3. Market Attractiveness Analysis By End-User
     • 3.4. Market Attractiveness Analysis By Region
   • 4. Industry Trends
5. Market Dynamics
   • 1. Market Evaluation
   • 2. Drivers
     • 2.1. Adoption of crucial tactics for product launches
   • 3. Restraints
     • 3.1. Lack of qualified and experienced personnel
   • 4. Opportunities
     • 4.1. Increasing prevalence of cardiovascular diseases
   • 5. Challenges
     • 5.1. Technical issues with sample storage and collecting

6. Global Cardiac Biomarkers Testing Market Analysis and Projection, By Biomarker Type
   • 1. Segment Overview
   • 2. Troponin
   • 3. Creatine Kinase-Mb
   • 4. B-Type Natriuretic Peptide
   • 5. Others
7. Global Cardiac Biomarkers Testing Market Analysis and Projection, By Application
   • 1. Segment Overview
   • 2. Acute Coronary Syndrome
   • 3. Congestive Heart Failure
   • 4. Myocardial Infarction
   • 5. Others
8. Global Cardiac Biomarkers Testing Market Analysis and Projection, By End-User
   • 1. Segment Overview
   • 2. Pathology Labs
   • 3. Hospitals
   • 4. Others
9. Global Cardiac Biomarkers Testing Market Analysis and Projection, By Regional Analysis
   • 1. Segment Overview
   • 2. North America
     • 2.1. U.S.
     • 2.2. Canada
     • 2.3. Mexico
   • 3. Europe
     • 3.1. Germany
     • 3.2. France
     • 3.3. U.K.
     • 3.4. Italy
     • 3.5. Spain
   • 4. Asia-Pacific
     • 4.1. Japan
     • 4.2. China
     • 4.3. India
   • 5. South America
     • 5.1. Brazil
   • 6. Middle East and Africa
     • 6.1. UAE
     • 6.2. South Africa

10. Global Cardiac Biomarkers Testing Market-Competitive Landscape
    • Overview
    • Market Share of Key Players in the Cardiac Biomarkers Testing Market
      • 2.1. Global Company Market Share
      • 2.2. North America Company Market Share
      • 2.3. Europe Company Market Share
      • 2.4. APAC Company Market Share
    • Competitive Situations and Trends
      • 3.1. Product Launches and Developments
      • 3.2. Partnerships, Collaborations, and Agreements
      • 3.3. Mergers & Acquisitions
      • 3.4. Expansions

11. Company Profiles
    • Beckman Coulter, Inc
      • 1.1. Business Overview
      • 1.2. Company Snapshot
      • 1.3. Company Market Share Analysis
      • 1.4. Company Product Portfolio
      • 1.5. Recent Developments
      • 1.6. SWOT Analysis
    • Hoffmann-La Roche Ltd
      • 2.1. Business Overview
      • 2.2. Company Snapshot
      • 2.3. Company Market Share Analysis
      • 2.4. Company Product Portfolio
      • 2.5. Recent Developments
      • 2.6. SWOT Analysis
    • Abbott, bioMérieux SA
      • 3.1. Business Overview
      • 3.2. Company Snapshot
      • 3.3. Company Market Share Analysis
      • 3.4. Company Product Portfolio
      • 3.5. Recent Developments
      • 3.6. SWOT Analysis
    • Thermo Fischer Scientific Inc
      • 4.1. Business Overview
      • 4.2. Company Snapshot
      • 4.3. Company Market Share Analysis
      • 4.4. Company Product Portfolio
      • 4.5. Recent Developments
      • 4.6. SWOT Analysis
    • Bio-Rad Laboratories Inc
      • 5.1. Business Overview
      • 5.2. Company Snapshot
      • 5.3. Company Market Share Analysis
      • 5.4. Company Product Portfolio
      • 5.5. Recent Developments
      • 5.6. SWOT Analysis
    • Eurolyser Diagnostica GmbH
      • 6.1. Business Overview
      • 6.2. Company Snapshot
      • 6.3. Company Market Share Analysis
      • 6.4. Company Product Portfolio
      • 6.5. Recent Developments
      • 6.6. SWOT Analysis
    • Diagnostic Automation / Cortez Diagnostics, Inc
      • 7.1. Business Overview
      • 7.2. Company Snapshot
      • 7.3. Company Market Share Analysis
      • 7.4. Company Product Portfolio
      • 7.5. Recent Developments
      • 7.6. SWOT Analysis
    • Randox Laboratories Ltd
      • 8.1. Business Overview
      • 8.2. Company Snapshot
      • 8.3. Company Market Share Analysis
      • 8.4. Company Product Portfolio
      • 8.5. Recent Developments
      • 8.6. SWOT Analysis
    • Tosoh Corporation
      • 9.1. Business Overview
      • 9.2. Company Snapshot
      • 9.3. Company Market Share Analysis
      • 9.4. Company Product Portfolio
      • 9.5. Recent Developments
      • 9.6. SWOT Analysis
    • DIALAB GmbH
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • CardioGenics Holdings Inc
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Lepu Medical Technology (Beijing) Co. Ltd.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Biosynex
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Siemens Healthcare GmbH
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis

List of Table

1. Global Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
2. Global Troponin, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
3. Global Creatine Kinase-Mb, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
4. Global B-Type Natriuretic Peptide, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
5. Global Others, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
6. Global Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
7. Global Acute Coronary Syndrome, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
8. Global Congestive Heart Failure, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
9. Global Myocardial Infarction, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
10. Global Others, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
11. Global Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
12. Global Pathology Labs, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
13. Global Hospitals, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
14. Global Others, Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
15. Global Cardiac Biomarkers Testing Market, By Region, 2023–2030 (USD Billion)
16. North America Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
17. North America Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
18. North America Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
19. USA Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
20. USA Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
21. USA Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)  
22. Canada Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
23. Canada Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
24. Canada Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
25. Mexico Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
26. Mexico Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
27. Mexico Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
28. Europe Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
29. Europe Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
30. Europe Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
31. Germany Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
32. Germany Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
33. Germany Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
34. France Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
35. France Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
36. France Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
37. UK Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
38. UK Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
39. UK Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
40. Italy Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
41. Italy Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
42. Italy Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
43. Spain Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
44. Spain Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
45. Spain Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
46. Asia Pacific Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
47. Asia Pacific Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
48. Asia Pacific Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
49. Japan Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
50. Japan Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
51. Japan Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
52. China Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
53. China Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
54. China Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
55. India Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
56. India Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
57. India Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
58. South America Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
59. South America Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
60. South America Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
61. Brazil Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
62. Brazil Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
63. Brazil Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
64. Middle East and Africa Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
65. Middle East and Africa Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
66. Middle East and Africa Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
67. UAE Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
68. UAE Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
69. UAE Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)
70. South Africa Cardiac Biomarkers Testing Market, By Biomarker Type, 2023–2030 (USD Billion)
71. South Africa Cardiac Biomarkers Testing Market, By Application, 2023–2030 (USD Billion)
72. South Africa Cardiac Biomarkers Testing Market, By End-User, 2023–2030 (USD Billion)

List of Figures 

1. Global Cardiac Biomarkers Testing Market Segmentation
2. Cardiac Biomarkers Testing Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Cardiac Biomarkers Testing Market Attractiveness Analysis By Biomarker Type
9. Global Cardiac Biomarkers Testing Market Attractiveness Analysis By Application
10. Global Cardiac Biomarkers Testing Market Attractiveness Analysis By End-User
11. Global Cardiac Biomarkers Testing Market Attractiveness Analysis By Region
12. Global Cardiac Biomarkers Testing Market: Dynamics
13. Global Cardiac Biomarkers Testing Market Share By Biomarker Type (2023 & 2030)
14. Global Cardiac Biomarkers Testing Market Share By Application (2023 & 2030)
15. Global Cardiac Biomarkers Testing Market Share By End-User (2023 & 2030)
16. Global Cardiac Biomarkers Testing Market Share by Regions (2023 & 2030)
17. Global Cardiac Biomarkers Testing Market Share by Company (2021)